224 related articles for article (PubMed ID: 38604809)
21. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
[TBL] [Abstract][Full Text] [Related]
22. Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression.
Finisguerra V; Dvorakova T; Formenti M; Van Meerbeeck P; Mignion L; Gallez B; Van den Eynde BJ
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37147018
[TBL] [Abstract][Full Text] [Related]
23. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.
Melchor J; Garcia-Lacarte M; Grijalba SC; Arnaiz-Leché A; Pascual M; Panizo C; Blanco O; Segura V; Novo FJ; Valero JG; Pérez-Galán P; Martinez-Climent JA; Roa S
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36854569
[TBL] [Abstract][Full Text] [Related]
24. Dezocine promotes T lymphocyte activation and inhibits tumor metastasis after surgery in a mouse model.
Song Q; Liu G; Liu D; Feng C
Invest New Drugs; 2020 Oct; 38(5):1342-1349. PubMed ID: 32170576
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.
Sharon D; Cathelin S; Mirali S; Di Trani JM; Yanofsky DJ; Keon KA; Rubinstein JL; Schimmer AD; Ketela T; Chan SM
Sci Transl Med; 2019 Oct; 11(516):. PubMed ID: 31666400
[TBL] [Abstract][Full Text] [Related]
26. The Combination of Venetoclax and Ixazomib Selectively and Efficiently Kills HIV-Infected Cell Lines but Has Unacceptable Toxicity in Primary Cell Models.
Alto A; Natesampillai S; Chandrasekar AP; Krogman A; Misra A; Shweta F; VanLith C; Yao JD; Cummins NW; Badley AD
J Virol; 2021 May; 95(12):. PubMed ID: 33827940
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway.
van Pul KM; Vuylsteke RJCLM; de Beijer MTA; van de Ven R; van den Tol MP; Stockmann HBAC; de Gruijl TD
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046620
[TBL] [Abstract][Full Text] [Related]
28. Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport.
Velez J; Pan R; Lee JT; Enciso L; Suarez M; Duque JE; Jaramillo D; Lopez C; Morales L; Bornmann W; Konopleva M; Krystal G; Andreeff M; Samudio I
Oncotarget; 2016 Aug; 7(32):51435-51449. PubMed ID: 27283492
[TBL] [Abstract][Full Text] [Related]
29. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.
de Weerdt I; Hofland T; de Boer R; Dobber JA; Dubois J; van Nieuwenhuize D; Mobasher M; de Boer F; Hoogendoorn M; Velders GA; van der Klift M; Remmerswaal EBM; Bemelman FJ; Niemann CU; Kersting S; Levin MD; Eldering E; Tonino SH; Kater AP
Blood Adv; 2019 Sep; 3(17):2642-2652. PubMed ID: 31506282
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.
Gangat N; Konopleva M; Patnaik MM; Jabbour E; DiNardo C; Al-Kali A; Foran JM; Granroth GL; Olteanu H; Kadia T; Tefferi A; Pemmaraju N
Am J Hematol; 2022 Feb; 97(2):E62-E67. PubMed ID: 34807470
[No Abstract] [Full Text] [Related]
31. Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts.
Arakawa Y; Jo U; Kumar S; Sun NY; Elloumi F; Thomas A; Roper N; Varghese DG; Takebe N; Zhang X; Ceribelli M; Holland DO; Beck E; Itkin Z; McKnight C; Wilson KM; Travers J; Klumpp-Thomas C; Thomas CJ; Hoang CD; Hernandez JM; Del Rivero J; Pommier Y
Cancer Res Commun; 2024 Mar; 4(3):834-848. PubMed ID: 38451783
[TBL] [Abstract][Full Text] [Related]
32. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
33. Combining T-cell-based immunotherapy with venetoclax elicits synergistic cytotoxicity to B-cell lines in vitro.
Murakami S; Suzuki S; Hanamura I; Yoshikawa K; Ueda R; Seto M; Takami A
Hematol Oncol; 2020 Dec; 38(5):705-714. PubMed ID: 32822067
[TBL] [Abstract][Full Text] [Related]
34. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
35. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
36. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.
Crassini K; Shen Y; Stevenson WS; Christopherson R; Ward C; Mulligan SP; Best OG
Br J Haematol; 2018 Aug; 182(3):360-372. PubMed ID: 29767411
[TBL] [Abstract][Full Text] [Related]
37. Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature.
Beziat G; Ysebaert L; Gaudin C; Steinmeyer Z; Balardy L
Leuk Res; 2019 Oct; 85():106199. PubMed ID: 31415942
[No Abstract] [Full Text] [Related]
38. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.
Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A
Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569
[TBL] [Abstract][Full Text] [Related]
39. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
40. Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy.
Si F; Liu X; Tao Y; Zhang Y; Ma F; Hsueh EC; Puram SV; Peng G
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
